利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.028 秒)

    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT
    6.
    发明申请
    MARKER FOR DIAGNOSIS OF BREAST CANCER, TEST METHOD, AND TEST KIT 审中-公开
    乳腺癌诊断标记，测试方法和测试包

    公开(公告)号：US20110028332A1

    公开(公告)日：2011-02-03

    申请号：US12934948

    申请日：2009-03-27

    申请人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi

    发明人： Masahiko Kuroda ,  Masami Tanaka ,  Kosuke Oikawa ,  Takayuki Mizutani ,  Masakatsu Takanashi

    IPC分类号： C40B30/00 ,  C07H21/02 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/178

    摘要： An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability.A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.

    摘要翻译： 本发明的一个实施方案提供了可以检测在早期阶段（临床阶段0）不能通过触诊或乳房X线照相检查或乳腺癌检测到的乳腺癌发作的标志物，测试方法和测试试剂盒，其为 简单，可靠性高。 与本发明实施方案的乳腺癌相关的标志物的特征在于是在血清或血浆中发现的微RNA。 更具体地，标记物在乳腺癌发作后或在乳腺早期（临床阶段0期间或之后）期间或之后存在于血清或血浆中存在的至少一种微RNA，其显着降低水平 与乳腺癌发病前或乳腺癌早期（临床阶段0之前）癌症相比较。

    METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF
    8.
    发明申请
    METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF 有权
    用于抑制信号传输的方法，其使用的信号传输抑制剂及其用途

    公开(公告)号：US20100062978A1

    公开(公告)日：2010-03-11

    申请号：US12294347

    申请日：2007-03-23

    申请人： Noriko Gotoh ,  Masahiko Kuroda ,  Nobuo Tsuchida

    发明人： Noriko Gotoh ,  Masahiko Kuroda ,  Nobuo Tsuchida

    IPC分类号： A61K38/16 ,  C12N5/08 ,  C07H21/00 ,  C07K14/00 ,  C07K7/08 ,  A61K31/7088 ,  C12Q1/68 ,  A61P35/00

    CPC分类号： G01N33/57484 ,  A61K38/00 ,  A61K48/00 ,  C07K14/47 ,  C12N9/1205 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N2800/52 ,  Y10S435/96 ,  Y10S435/968

    摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

    摘要翻译： 本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。 可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。 可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。 这样的多肽和核酸可以用作例如信号传导抑制剂。 此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

    Oncogene, recombinant protein derived therefrom, and uses thereof
    9.
    发明授权
    Oncogene, recombinant protein derived therefrom, and uses thereof 有权
    癌基因，从其衍生的重组蛋白及其用途

    公开(公告)号：US07358350B2

    公开(公告)日：2008-04-15

    申请号：US10758562

    申请日：2004-01-16

    申请人： Akira Saito ,  Masahiko Kuroda

    发明人： Akira Saito ,  Masahiko Kuroda

    IPC分类号： C07H21/02 ,  C07H21/04

    CPC分类号： C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.

    摘要翻译： 本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制， 提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。 具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。 1，特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。 2号

    Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof
    10.
    发明授权
    Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof 有权
    抑制信号转导的方法，其中使用的信号转导抑制剂及其用途

    公开(公告)号：US08173365B2

    公开(公告)日：2012-05-08

    申请号：US12294347

    申请日：2007-03-23

    申请人： Noriko Gotoh ,  Masahiko Kuroda ,  Nobuo Tsuchida

    发明人： Noriko Gotoh ,  Masahiko Kuroda ,  Nobuo Tsuchida

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： G01N33/57484 ,  A61K38/00 ,  A61K48/00 ,  C07K14/47 ,  C12N9/1205 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N2800/52 ,  Y10S435/96 ,  Y10S435/968

    摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

    摘要翻译： 本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。 可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。 可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。 这样的多肽和核酸可以用作例如信号传导抑制剂。 此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。